Hansa Biopharma AB
STO:HNSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Taste . Gourmet Group Ltd
HKEX:8371
|
HK |
|
Xiaomi Corp
HKEX:81810
|
CN |
|
Sao Carlos Empreendimentos e Participacoes SA
BOVESPA:SCAR3
|
BR |
Hansa Biopharma AB
Inventory
Hansa Biopharma AB
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hansa Biopharma AB
STO:HNSA
|
Inventory
kr6.1m
|
CAGR 3-Years
85%
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Inventory
kr145m
|
CAGR 3-Years
37%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Inventory
kr413m
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Inventory
kr5.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
11%
|
CAGR 10-Years
21%
|
|
|
BioArctic AB
STO:BIOA B
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hansa Biopharma AB
Glance View
Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 141 full-time employees. The company went IPO on 2007-10-17. The Company’s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
See Also
What is Hansa Biopharma AB's Inventory?
Inventory
6.1m
SEK
Based on the financial report for Dec 31, 2025, Hansa Biopharma AB's Inventory amounts to 6.1m SEK.
What is Hansa Biopharma AB's Inventory growth rate?
Inventory CAGR 5Y
129%
Over the last year, the Inventory growth was 135%. The average annual Inventory growth rates for Hansa Biopharma AB have been 85% over the past three years , 129% over the past five years .
